57 related articles for article (PubMed ID: 30679305)
1. Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies.
Montvida O; Cai X; Paul SK
Diabetes Care; 2019 Apr; 42(4):644-650. PubMed ID: 30679305
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
3. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.
Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG
Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663
[TBL] [Abstract][Full Text] [Related]
4. Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study.
Hu H; Hori A; Nishiura C; Sasaki N; Okazaki H; Nakagawa T; Honda T; Yamamoto S; Tomita K; Miyamoto T; Nagahama S; Uehara A; Yamamoto M; Murakami T; Shimizu C; Shimizu M; Eguchi M; Kochi T; Imai T; Okino A; Kuwahara K; Kashino I; Akter S; Kurotani K; Nanri A; Kabe I; Mizoue T; Kunugita N; Dohi S;
PLoS One; 2016; 11(7):e0159071. PubMed ID: 27437997
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in the control of cardiovascular risk factors in patients with type 2 diabetes -a cross-sectional study.
Sekerija M; Poljicanin T; Erjavec K; Liberati-Cizmek AM; Prašek M; Metelko Z
Intern Med; 2012; 51(2):161-6. PubMed ID: 22246483
[TBL] [Abstract][Full Text] [Related]
6. Role of therapeutic inertia in glycemic control according to individualized objectives in a cohort of patients with type 2 diabetes. Results from CONCARDIA2.
Hidalgo Rodríguez A; Martín Enguix D; Aguirre Rodríguez JC; Sánchez Cambronero M
Endocrinol Diabetes Nutr (Engl Ed); 2022; 69(7):458-465. PubMed ID: 36038497
[TBL] [Abstract][Full Text] [Related]
7. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
Jansson SP; Svärdsudd K; Andersson DK
Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
[TBL] [Abstract][Full Text] [Related]
8. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
[TBL] [Abstract][Full Text] [Related]
9. Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database.
Sidorenkov G; Voorham J; de Zeeuw D; Haaijer-Ruskamp FM; Denig P
BMJ Qual Saf; 2013 Apr; 22(4):339-47. PubMed ID: 23386729
[TBL] [Abstract][Full Text] [Related]
10. Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study.
Voorham J; Haaijer-Ruskamp FM; van der Meer K; de Zeeuw D; Wolffenbuttel BH; Hoogenberg K; Denig P;
Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1078-86. PubMed ID: 20687048
[TBL] [Abstract][Full Text] [Related]
11. Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study.
Wan EYF; Yu EYT; Chin WY; Fung CSC; Fong DYT; Choi EPH; Chan AKC; Lam CLK
Diabetes Care; 2018 Jun; 41(6):1134-1141. PubMed ID: 29592967
[TBL] [Abstract][Full Text] [Related]
12. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
13. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
14. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
15. [Inertia and treatment compliance in patients with type 2 diabetes in primary care].
López-Simarro F; Brotons C; Moral I; Cols-Sagarra C; Selva A; Aguado-Jodar A; Miravet-Jiménez S
Med Clin (Barc); 2012 Apr; 138(9):377-84. PubMed ID: 22036458
[TBL] [Abstract][Full Text] [Related]
16. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
17. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.
Gyberg V; De Bacquer D; De Backer G; Jennings C; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L; Amouyel P; Bruthans J; Conde AC; Cifkova R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pająk A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
Cardiovasc Diabetol; 2015 Oct; 14():133. PubMed ID: 26427624
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
19. [Metformin in the treatment of type 2 diabetes in overweighted or obese patients].
Martín Muñoz MC; Díaz JM; Muros Bayo JM; González Alvaro A; Costa Zamora P
An Med Interna; 2005 Dec; 22(12):579-85. PubMed ID: 16454597
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
